Cabaletta Bio, Inc.
(NASDAQ : CABA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.81%179.510.0%$1748.23m
NVAXNovavax, Inc. -3.09%95.4078.2%$679.48m
AMGNAmgen, Inc. -0.35%233.011.4%$534.09m
BIIBBiogen, Inc. -0.74%232.071.8%$500.42m
GILDGilead Sciences, Inc. -0.75%69.901.0%$468.13m
BNTXBioNTech SE -1.87%166.070.0%$443.23m
REGNRegeneron Pharmaceuticals, Inc. 1.83%622.382.7%$403.41m
ILMNIllumina, Inc. 1.23%387.853.3%$390.37m
VRTXVertex Pharmaceuticals, Inc. 0.14%231.401.9%$334.69m
SNSSSunesis Pharmaceuticals, Inc. -2.33%2.930.7%$204.82m
EXASEXACT Sciences Corp. 0.07%77.4717.9%$154.26m
ARNAArena Pharmaceuticals, Inc. -0.39%91.6213.7%$144.85m
ALNYAlnylam Pharmaceuticals, Inc. 0.04%139.258.2%$139.18m
INCYIncyte Corp. -0.33%74.762.4%$132.47m
BMRNBioMarin Pharmaceutical, Inc. -0.02%86.694.2%$106.18m

Company Profile

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.